Pharmaceutical US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the Phase III VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV), a rare blood cancer, were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. 4 March 2025